Login / Signup

The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Christophe D'EnfertAnn-Kristin KauneLeovigildo-Rey AlabanSayoni ChakrabortyNathaniel ColeMargot DelavyDaria KosmalaBenoît MarsauxRicardo Fróis-MartinsMoran MorelliDiletta RosatiMarisa ValentineZixuan XieYoan EmritlollPeter A WarnFrédéric BequetMarie-Elisabeth BougnouxStephanie BornesMark S GresnigtBernhard HubeIlse D JacobsenMélanie LegrandSalomé Leibundgut-LandmannChaysavanh ManichanhCarol A MunroMihai G NeteaKarla QueirozKarine RogetVincent ThomasClaudia ThoralPieter Van den AbbeeleAlan W WalkerAlistair J P Brown
Published in: FEMS microbiology reviews (2021)
Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.
Keyphrases
  • candida albicans
  • biofilm formation
  • end stage renal disease
  • ejection fraction
  • cell wall
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • cystic fibrosis
  • drug induced